139 related articles for article (PubMed ID: 2244188)
1. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
4. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
Lee YC; Pan HW; Peng SY; Lai PL; Kuo WS; Ou YH; Hsu HC
Eur J Cancer; 2007 Mar; 43(4):736-44. PubMed ID: 17267202
[TBL] [Abstract][Full Text] [Related]
6. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C
Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949
[TBL] [Abstract][Full Text] [Related]
7. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2.
Koivunen E; Itkonen O; Halila H; Stenman UH
Cancer Res; 1990 Apr; 50(8):2375-8. PubMed ID: 2180568
[TBL] [Abstract][Full Text] [Related]
8. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
[TBL] [Abstract][Full Text] [Related]
9. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a tumor-associated serine protease.
Stenman UH; Koivunen E; Vuento M
Biol Chem Hoppe Seyler; 1988 May; 369 Suppl():9-14. PubMed ID: 3202976
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
12. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
13. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH
Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948
[TBL] [Abstract][Full Text] [Related]
14. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
15. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Schalken J
Eur Urol; 2007 Dec; 52(6):1679. PubMed ID: 17306439
[No Abstract] [Full Text] [Related]
17. [Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus].
Ilić RS; Mihailović D
Srp Arh Celok Lek; 1992; 120(3-4):97-9. PubMed ID: 1465666
[TBL] [Abstract][Full Text] [Related]
18. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Gouyer V; Fontaine D; Dumont P; de Wever O; Fontayne-Devaud H; Leteurtre E; Truant S; Delacour D; Drobecq H; Kerckaert JP; de Launoit Y; Bracke M; Gespach C; Desseyn JL; Huet G
Oncogene; 2008 Jul; 27(29):4024-33. PubMed ID: 18317448
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
20. Effect of intracavitary radiotherapy on tumor-associated trypsin inhibitor (TATI) in patients with cervical and endometrial cancer.
Lehtovirta P; Turpeinen U; Stenman UH
Gynecol Oncol; 1990 Jul; 38(1):110-3. PubMed ID: 2354815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
